ReviewNPJ vaccines2021
Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases.
Review in NPJ vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 2 syntheses or guidelines pooled it, 248 citations in OpenAlex.
- Occupational health and safety in the wake of COVID-19: insights from India's workforce.Frontiers in public health · 2026Pooled it
- The efficacy and effectiveness of COVID-19 vaccines around the world: a mini-review and meta-analysis.Annals of clinical microbiology and antimicrobials · 2023Pooled it
- Efficacy of add-on Ayurveda and Yoga intervention in health care workers of tertiary care hospital during COVID-19: Randomized controlled trial.Complementary therapies in clinical practice · 2022Trial
- SARS-CoV-2 vaccine induced humoral & cell-mediated immune responses in Indian cohort of rheumatoid arthritis.The Indian journal of medical research · 2025Article
- The Association of SARS-CoV-2 Infection and COVID-19 Vaccination With Sudden Death: An Explorative Review.Cureus · 2025Review
- Revisiting Public Trust and Media Influence During COVID-19 Post-Vaccination Era-Waning of Anxiety and Depression Levels Among Skilled Workers and Students in Serbia.Behavioral sciences (Basel, Switzerland) · 2025Article
- Assessing breakthrough infections: Covishield (late schedule) versus Covaxin - A prospective comparative analysis in the general population.Journal of family medicine and primary care · 2025Article
- Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2.Vaccines · 2025Review
- Post COVID Condition and Long-Term COVID-19 Impact on Hepatic Decompensation and Survival in Cirrhosis: A Propensity Matched Observational Study.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- CoWIN twitter dataset: A comprehensive collection of public discourse on India's COVID-19 vaccination platform.Data in brief · 2025Article
- Preparing for future pandemics: A qualitative exploration of social media in light of the COVID-19 pandemic and vaccine hesitancy.PLOS global public health · 2025Article
- BharatSim: An agent-based modelling framework for India.PLoS computational biology · 2024Article
- India's Potential as a Leader in Cancer Care Progress in the Future: A Synthetic Interdisciplinary Perspective.Cureus · 2024Review
- Article
- Sustaining the mobile medical units to bring equity in healthcare: a PLS-SEM approach.International journal for equity in health · 2024Article
- Review
- COVID-19 vaccine: Culprit or innocent bystander in a rare adverse gastro-intestinal surgical event? A case report with review of literature.Journal of family medicine and primary care · 2024Article
- Progress with COVID vaccine development and implementation.NPJ vaccines · 2024Article
- Acceptance and expectations of healthcare workers and community during the COVID-19 vaccine rollout in Bhavnagar city, western India: a qualitative exploration.BMC health services research · 2024Article
- Adverse events following Covaxin administration among adolescents (15-18 years) - A pharmacovigilance study in a district in Northern India.Journal of family medicine and primary care · 2024Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Free vaccination against COVID-19 commenced in India on January 16, 2021, and the government is urging all of its citizens to be immunized, in what is expected to be the largest vaccination program in the world. Out of the eight COVID-19 vaccines that are currently under various stages of clinical trials in India, four were developed in the country. India's drug regulator has approved restricted emergency use of Covishield (the name employed in India for the Oxford-AstraZeneca vaccine) and Covaxin, the home-grown vaccine produced by Bharat Biotech. Indian manufacturers have stated that they have the capacity to meet the country's future needs for COVID-19 vaccines. The manpower and cold-chain infrastructure established before the pandemic are sufficient for the initial vaccination of 30 million healthcare workers. The Indian government has taken urgent measures to expand the country's vaccine manufacturing capacity and has also developed an efficient digital system to address and monitor all the aspects of vaccine administration.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.